Today’s Solutions: September 26, 2022

Being diagnosed with cancer is probably one of the most devastating experiences one can have. However, once tumors are successfully removed, living with the fear that some cancer cells may remain, regrow, and respread through the body is a particular torment for the patient, their loved ones, and their family.

Thankfully, Quanyin Hu, Ph.D., and his team of researchers at the University of Wisconsin-Madison developed a solution: a hydrogel that prevents or slows tumor regrowth.

How does it work?

To prevent cancer from returning post-surgery, the gel releases two strategically selected compounds. Firstly, a drug called Pexidartinib is released. This drug is already used to discourage tumor-associated macrophages (TAMs), immune cells that “switch sides” and instead of fighting cancer off, help create a pro-cancer environment. 

The second drug is composed of PD-1 antibodies, which help train T cells to identify and attack cancer cells. These two drugs work together to prevent the creation of a microenvironment that supports cancer growth and helps the immune system get rid of any cancer cells that might remain after surgery. Fortuitously, the gel is also designed to biodegrade safely in the body once its work is complete.

So far, the gel has been tested in mouse models of several different types of cancer such as colon cancer, melanoma, sarcoma, and triple-negative breast cancer. The gel proved to reduce the recurrence and metastasis of all cancers included in the study and extended the survival rates of the mice. The control animals who received no gel would die within 36 days, while survival rates of the treated mice ranged between 50 and 66 percent, depending on the type of cancer.

Another benefit of hydrogel is its local application, which reduces the chances of side effects arising. This is a big concern for other cancer treatments, such as chemotherapy, which affects the whole body.

“We are really glad to see that this local strategy can work against so many different kinds of tumors, especially these non-immunogenic tumors,” Quanyin Hu states. “We are even more glad to see this local treatment can inhibit tumor metastasis.”

The team will continue administering animal tests with the hope that the gel will soon be ready for human trials.

Source study: Nature CommunicationsDepletion of tumor-associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment

Solutions News Source Print this article
More of Today's Solutions

6 family-strengthening strategies to try out this Family Day

These days, parents and children have hectic schedules jammed packed with work, school, and all the related responsibilities that pop up. While leading a ...

Read More

These herbs and spices can boost longevity

Aging is inevitable, but oxidative stress and inflammation are believed to accelerate this process. The foods we eat have a big impact on our ...

Read More

How ketamine can help fight depression

Quick acting aid A recent review from the University of Exeter, has shown that the sedative drug ketamine, has therapeutic effects in regards to ...

Read More

5 eating habits proven to lower your risk of heart disease

Whether we like it or not, our diets play a huge role in determining our risk of developing chronic diseases—especially when it comes to ...

Read More